Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recMAGE-A3 + AS15 ASCI (GSK)
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
recMAGE-A3 + AS15 ASCI is an investigational antigen-specific cancer immunotherapeutic (ASCI) consisting of a recombinant MAGE-A3 protein combined with the AS15 adjuvant system. AS15 is a proprietary adjuvant system containing CpG 7909, monophosphoryl lipid A (MPL), and QS-21. The therapy is designed to induce a specific immune response against tumor cells expressing the Melanoma-Associated Antigen A3 (MAGE-A3), a tumor-associated antigen frequently expressed in various malignancies, including bladder cancer. It was evaluated as an adjuvant treatment in patients with MAGE-A3 positive muscle-invasive bladder cancer (MIBC) who had undergone radical cystectomy to prevent disease recurrence. The development of the MAGE-A3 ASCI program was largely halted by GSK following the failure of Phase III trials in melanoma and non-small cell lung cancer.
- Other names
- MAGE-A3 ASCIMAGE-A-3 ASCIMAGE-A 3 ASCIrecMAGE-A3 + AS15MAGE-A3 cancer immunotherapeuticMAGE-A-3 cancer immunotherapeuticMAGE-A 3 cancer immunotherapeutic
02
Targets
MAGEA3 (Melanoma-associated antigen 3)
Beyond the preview
Go deeper on recMAGE-A3 + AS15 ASCI (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recMAGE-A3 + AS15 ASCI (GSK).